Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Maryland: - UM Upper Chesapeake Medical Center — Bel Air, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Maryland: - Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Maryland: - The John Hopkins Hospital — Baltimore, Maryland
- Maryland Oncology Hematology- Columbia — Rockville, Maryland
Phase 2 Recruiting Industry
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, th…
Sponsor: Black Diamond Therapeutics, Inc.
NCT ID: NCT07326566
Sites in Maryland: - Johns Hopkins Sidney Kimmel Cancer Center - Baltimore — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Maryland: - The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine — Baltimore, Maryland
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Maryland: - John Hopkins Medical Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated…
Sponsor: Scott R. Plotkin, MD, PhD
NCT ID: NCT04374305
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed. Objective: To see if a study d…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05588141
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the brain and spi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161519
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Sponsor: Boston Scientific Corporation
NCT ID: NCT05303467
Sites in Maryland: - Johns Hopkins Interventional Radiology Center — Baltimore, Maryland
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Maryland: - Advanced Molecular Imaging and Therapy — Glen Burnie, Maryland
- United Theranostics - Chesapeake — Glen Burnie, Maryland
Phase 1 Recruiting Academic/Other
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer pla…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05083754
Sites in Maryland: - Johns Hopkins Medical Institution — Baltimore, Maryland
EARLY Phase 1 Recruiting Academic/Other
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutan…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06610682
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
Phase 1 Recruiting Academic/Other
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediat…
Sponsor: University of Maryland, Baltimore
NCT ID: NCT04772456
Sites in Maryland: - Rosy Njonkou Tchoquessi — Baltimore, Maryland
Phase 1 Recruiting Industry
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DL…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT04541082
Sites in Maryland: - National Institutes of Health — Bethesda, Maryland
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maryland: - Massive Bio SYNERGY-AI site — Baltimore, Maryland
- Massive Bio SYNERGY-AI site — Bethesda, Maryland
- Massive Bio SYNERGY-AI site — Silver Spring, Maryland
- Massive Bio SYNERGY-AI site — Towson, Maryland